In addition, an increase in GP88 protein has been described in relation to different cancer treatment resistance mechanisms [46], especially in endocrine-related tumors, such as letrozole and tamoxifen resistance in breast cancer cells [20,47] and chemoresistance to cisplatin in ovarian cancer cell lines [48]. The gene discussed is GRN; the disease is ovarian cancer.